Celgene Corporation company logo

# RNN 1st Gen Model Celgene Corporation Pharmaceutical preparations

Prediction models:
76.62% successful of 77 deals
$ 95.61 Last close price
at 23-feb-2018

CELG

Model's trade recommendations -6.66% Return for period

9.81% Annual return

$70.62B Market Cap

β 1.49  

CELG

Model (following trade recommendations)

CELG

Underlying stock

S&P 500

Index
Return for period -6.66%
-9.09%
1.78%
52wk return -4.90%
-19.13%
16.82%
52wk Range
91.01—146.52
2000.54—2399.63
Sortino ratio 0.99
Sharpe ratio 0.79
Norm. RMSE 0.77%
Downside risk 9.92%
Volatility 12.52%
  • BUY Analysts consensus recommendation

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Their portfolio of commercial products include REVLIMID, VIDAZA, THALOMID, POMALYST/IMNOVID, ABRAXANE, OTEZLA, ISTODAX and IDHIFA. The drug candidates in their pipeline are at various stages of preclinical and clinical development. These candidates include their IMiDs compounds, which are a proprietary class of compounds that have certain immunomodulatory and other biologically important properties in addition to their leading oral anti-inflammatory agents and cellular therapies. They believe their commercial stage products and the depth of their product pipeline, provide the catalysts for future growth.

Industry sector: Medical

Sector classification: Pharmaceutical preparations

Deep Learning based analysis and prediction model for Celgene Corporation (CELG) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.

Model is in the production pipeline since Oct. 2, 2015.

Market data for CELG model training are being downloaded from the Quandl premium datasets on a daily basis.

Model is being retrained on a daily basis.

Float 745M
P/E 13.69
Shares Outstanding 752M
% Held by Insiders 0.95%
% Held by Institutions 77.84%
EPS (last reported FY) $6.84
EPS (last reported Q) $1.87
EPS, estimated (last reported Q) $1.78
Total revenues $13 B
Net income $3 B